Somatic TP53 variants are common across a host of cancer types, most commonly colorectal and head and neck cancer, and TP53-mutant cancers demonstrate higher rates of chemo- and or radio-therapeutic resistance, increased risk of relapse, and reduced survival [38,39]. This evidence concerns the gene TP53 and head and neck cancer.